A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver Function
Starting soon · Phase 1
Conditions studied: Overweight, Obesity
In brief
The study is testing a new study medicine to treat people with overweight/obesity and type 2 diabetes. The aim of this study is to see if it is safe and to find out how it works in people with reduced liver function and people with normal liver function.
Key facts
- Study ID
- NCT07587710
- Run by
- Novo Nordisk A/S
- People needed
- 35
- Starts
- 2026-05-13
- Expected to finish
- 2027-12-01
- Last updated by the study team
- 2026-05-14
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Male or female (sex at birth).
- Age 18-80 years (both inclusive) at the time of signing informed consent.
- Participants with stable hepatic impairment classified as Child-Pugh grade A, B or C as assessed by the investigator. Stable hepatic impairment is defined as no clinically significant change in disease status, as judged by the investigator.
You may not qualify if…
- Known or suspected hypersensitivity to study intervention(s) or related products.
- Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method.
Where it is running
- Summit Clinical Research s.r.o. — Bratislava, Slovakia
- Summit Clinical Research s.r.o. — Malacky, Slovakia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.